Tesamorelin 10mg

Tesamorelin | 10mg

Tesamorelin is sold as a 10 mg lyophilised powder.

Tesamorelin is a synthetic form of growth hormone-releasing hormone (GHRH), engineered with a structural modification that protects it from rapid enzymatic breakdown. This added stability allows it to act on the pituitary gland over a more sustained period than native GHRH, prompting the gland to release growth hormone in a manner that follows the body’s own pulsatile pattern.

Much of the scientific attention given to Tesamorelin stems from this stabilised GHRH activity and its downstream effects. By raising growth hormone levels, it influences the production of insulin-like growth factor-1 (IGF-1) — a pathway connected to protein synthesis, tissue repair, and the regulation of body composition. A notable portion of the research literature has focused specifically on its relationship to adipose tissue, particularly visceral fat metabolism, which distinguishes it from several other compounds that act on the growth hormone axis. Studies have also examined its potential links to lean tissue maintenance and metabolic regulation, making it a recurring subject of investigation into how GHRH-based compounds affect the body.

The molecule tesamorelin is FDA-approved as the prescription medication Egrifta, indicated for the reduction of excess visceral abdominal fat. This product is supplied as a research-use preparation.

Bacteriostatic water is not included.